Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Limited submitted a Form 144 notice reporting proposed sales of ordinary shares by holders, including 110,668 and 33,512 shares described as "shares from rollover" and compensation-related sales. The filing lists a prior sale of 62,102 shares on 03/17/2026 with a reported value of 1,871,815.26.
Teva Pharmaceutical Industries Limited submitted a Form 144 notice reporting proposed sales of ordinary shares by holders, including 110,668 and 33,512 shares described as "shares from rollover" and compensation-related sales. The filing lists a prior sale of 62,102 shares on 03/17/2026 with a reported value of 1,871,815.26.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales tied to recent vesting of stock awards. The filing lists vesting events on 03/04/2026 (11,363 shares) and 03/05/2026 (9,895 shares). It records two dispositions by Christine Fox: 9,908 shares on 03/04/2026 for $321,658.26 and 7,924 shares on 03/05/2026 for $250,940.40.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales tied to recent vesting of stock awards. The filing lists vesting events on 03/04/2026 (11,363 shares) and 03/05/2026 (9,895 shares). It records two dispositions by Christine Fox: 9,908 shares on 03/04/2026 for $321,658.26 and 7,924 shares on 03/05/2026 for $250,940.40.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries Ltd. is asking shareholders to reappoint Dr. Sol J. Barer as director through 2029, approve executive pay on an advisory basis, and ratify Kesselman & Kesselman (PwC network) as auditor through the 2027 meeting. The Board highlights progress on its “Pivot to Growth” strategy, emphasizing double‑digit growth for key innovative drugs AUSTEDO, UZEDY (including an FDA indication expansion for Bipolar I disorder) and AJOVY, as well as advancement of late‑stage assets like olanzapine LAI and duvakitug, which generated a $500 million Phase 3 milestone payment recorded as 2025 revenue. Teva reports 2025 global revenue growth in local currency, continued net debt reduction, and a stronger balance sheet supported by sustainable finance, including about $7.5 billion of sustainability‑linked bonds and a $1.8 billion sustainability‑linked revolving credit facility. The proxy details Board composition, committee structure, AI and cybersecurity oversight, human capital initiatives for Teva’s 33,950 employees, and an executive compensation framework heavily weighted to variable, performance‑based pay, alongside strengthened stock‑ownership guidelines and no hedging or repricing of underwater options.
Teva Pharmaceutical Industries Ltd. is asking shareholders to reappoint Dr. Sol J. Barer as director through 2029, approve executive pay on an advisory basis, and ratify Kesselman & Kesselman (PwC network) as auditor through the 2027 meeting. The Board highlights progress on its “Pivot to Growth” strategy, emphasizing double‑digit growth for key innovative drugs AUSTEDO, UZEDY (including an FDA indication expansion for Bipolar I disorder) and AJOVY, as well as advancement of late‑stage assets like olanzapine LAI and duvakitug, which generated a $500 million Phase 3 milestone payment recorded as 2025 revenue. Teva reports 2025 global revenue growth in local currency, continued net debt reduction, and a stronger balance sheet supported by sustainable finance, including about $7.5 billion of sustainability‑linked bonds and a $1.8 billion sustainability‑linked revolving credit facility. The proxy details Board composition, committee structure, AI and cybersecurity oversight, human capital initiatives for Teva’s 33,950 employees, and an executive compensation framework heavily weighted to variable, performance‑based pay, alongside strengthened stock‑ownership guidelines and no hedging or repricing of underwater options.
Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.
Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.
Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.
Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.
Teva Pharmaceutical Industries reported a Form 144 notification for the proposed sale of 62,102 ordinary shares, listed for sale through Citigroup Global Markets Inc. on the NYSE. The shares are identified as rollover/compensation ordinary shares with trade dates listed in March 2026.
Teva Pharmaceutical Industries reported a Form 144 notification for the proposed sale of 62,102 ordinary shares, listed for sale through Citigroup Global Markets Inc. on the NYSE. The shares are identified as rollover/compensation ordinary shares with trade dates listed in March 2026.
Teva Pharmaceutical Industries officer Mark Sabag reported the vesting and settlement of 15,723 restricted share units on March 5, 2026. These units were converted at $0.00 per share into 15,723 ordinary shares, increasing his direct holdings to 287,042 ordinary shares.
Following the transaction, he also held 47,170 restricted share units. The RSUs were originally granted on March 5, 2025, with additional tranches of 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each RSU represents a right to one ordinary share or its cash value.
Teva Pharmaceutical Industries officer Mark Sabag reported the vesting and settlement of 15,723 restricted share units on March 5, 2026. These units were converted at $0.00 per share into 15,723 ordinary shares, increasing his direct holdings to 287,042 ordinary shares.
Following the transaction, he also held 47,170 restricted share units. The RSUs were originally granted on March 5, 2025, with additional tranches of 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each RSU represents a right to one ordinary share or its cash value.
Teva Pharmaceutical Industries Chief Accounting Officer Amir Weiss reported equity compensation activity involving restricted share units. On March 5, 2026, 3,537 restricted share units were converted into 3,537 ordinary shares at no cash exercise price as part of a previously granted award.
The footnotes explain this grant was made on March 5, 2025, with 3,537 units vesting on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. After this transaction, Weiss directly held 30,695 ordinary shares and 10,613 restricted share units.
Teva Pharmaceutical Industries Chief Accounting Officer Amir Weiss reported equity compensation activity involving restricted share units. On March 5, 2026, 3,537 restricted share units were converted into 3,537 ordinary shares at no cash exercise price as part of a previously granted award.
The footnotes explain this grant was made on March 5, 2025, with 3,537 units vesting on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. After this transaction, Weiss directly held 30,695 ordinary shares and 10,613 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.
On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.
Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.
On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.